Journal
NPJ VACCINES
Volume 6, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41541-021-00321-8
Keywords
-
Categories
Funding
- UCLA AIDS Institute
- Charity Treks
- National Institutes of Health [AI141390]
Ask authors/readers for more resources
A vaccine generated using the LVS Delta capB vector platform has shown protection in golden Syrian hamsters, potentially serving as a universal vaccine against pandemic causing beta-coronaviruses, with good safety and affordability.
To generate an inexpensive readily manufactured COVID-19 vaccine, we employed the LVS Delta capB vector platform, previously used to generate potent candidate vaccines against Select Agent diseases tularemia, anthrax, plague, and melioidosis. Vaccines expressing SARS-CoV-2 structural proteins are constructed using the LVS Delta capB vector, a highly attenuated replicating intracellular bacterium, and evaluated for efficacy in golden Syrian hamsters, which develop severe COVID-19-like disease. Hamsters immunized intradermally or intranasally with a vaccine co-expressing the Membrane and Nucleocapsid proteins and challenged 5 weeks later with a high dose of SARS-CoV-2 are protected against severe weight loss and lung pathology and show reduced viral loads in the oropharynx and lungs. Protection correlates with anti-Nucleocapsid antibody. This potent vaccine should be safe; inexpensive; easily manufactured, stored, and distributed; and given the high homology between Membrane and Nucleocapsid proteins of SARS-CoV and SARS-CoV-2, potentially serve as a universal vaccine against the SARS subset of pandemic causing beta-coronaviruses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available